NCT06126575View on ClinicalTrials.gov

A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

November 11, 2024

Study Completion Date

November 11, 2024

Conditions
Hepatic Impairment
Interventions
DRUG

Elacestrant dihydrochloride

A single oral dose of 200 mg elacestrant (2 x 100 mg tablets).

Trial Locations (3)

33016

Floridian Clinical Research, Miami

78215

American Research Corp, San Antonio

92399

Inland Empire Clinical Trials, LLC, Yucaipa

All Listed Sponsors
lead

Stemline Therapeutics, Inc.

INDUSTRY